ATE350060T1 - Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten - Google Patents

Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten

Info

Publication number
ATE350060T1
ATE350060T1 AT99938591T AT99938591T ATE350060T1 AT E350060 T1 ATE350060 T1 AT E350060T1 AT 99938591 T AT99938591 T AT 99938591T AT 99938591 T AT99938591 T AT 99938591T AT E350060 T1 ATE350060 T1 AT E350060T1
Authority
AT
Austria
Prior art keywords
agents
preventing
active component
receptor antibodies
contain anti
Prior art date
Application number
AT99938591T
Other languages
English (en)
Inventor
Akihiro Funakoshi
Kyoko Miyasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE350060T1 publication Critical patent/ATE350060T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99938591T 1998-08-24 1999-08-23 Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten ATE350060T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25179698 1998-08-24
JP5430299 1999-03-02

Publications (1)

Publication Number Publication Date
ATE350060T1 true ATE350060T1 (de) 2007-01-15

Family

ID=26395047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99938591T ATE350060T1 (de) 1998-08-24 1999-08-23 Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten

Country Status (11)

Country Link
US (1) US8440196B1 (de)
EP (1) EP1108435B1 (de)
JP (1) JP4711507B2 (de)
AT (1) ATE350060T1 (de)
AU (1) AU757261B2 (de)
CA (1) CA2341239C (de)
DE (1) DE69934698T2 (de)
DK (1) DK1108435T3 (de)
ES (1) ES2276525T3 (de)
PT (1) PT1108435E (de)
WO (1) WO2000010607A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP3192528A1 (de) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formularierung anti-il-6r antikörper-enthaltender lösungen die einen zucker als stabilisator beinhalten
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (en) * 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
AU2006300234B2 (en) * 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP3135298B1 (de) 2006-01-27 2018-06-06 Keio University Therapeutische mittel für erkrankungen im zusammenhang mit choroidaler neovaskularisation
EP2025346B1 (de) 2006-04-07 2016-08-10 Osaka University Mittel zur förderung der muskelregeneration
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US9981415B2 (en) 2007-09-10 2018-05-29 Ehc Canada, Inc. Method and apparatus for extrusion of thermoplastic handrail
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
KR101709492B1 (ko) 2009-03-18 2017-02-23 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2578233B1 (de) * 2010-05-28 2017-04-26 National Cancer Center Therapeutischer wirkstoff gegen bauchspeicheldrüsenkrebs
EP2787007A3 (de) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subkutan verabreichter ANTI-IL-6-Rezeptorantikörper
WO2012067150A1 (ja) * 2010-11-16 2012-05-24 三菱化学株式会社 Interleukin-6 receptor subunit beta蛋白質による脳梗塞の検査方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013176471A1 (ko) 2012-05-21 2013-11-28 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN107531001B (zh) 2015-05-07 2020-08-04 Ehc加拿大股份公司 具有增强的机械性质的紧凑型复合扶手
EP3305325B1 (de) 2015-06-04 2025-07-30 National Center of Neurology and Psychiatry Wirkstoff zur therapie von geisteskrankheiten mit il-6-hemmer als wirkstoff
CA2987973C (en) 2015-06-19 2023-05-23 Ehc Canada, Inc. Method and apparatus for extrusion of thermoplastic handrail
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN110072551B (zh) 2016-12-14 2023-05-23 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
EP3596175A4 (de) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation Nanopartikel zur abgabe von chemopräventiven mitteln
EP3600416B1 (de) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem immunmodulatorischen mittel, das mit einer einnehmbaren vorrichtung freigesetzt wird.
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810268A1 (de) 2018-06-20 2021-04-28 Progenity, Inc. Behandlung einer erkrankung des magen-darm-traktes mit einem il-12/il-23-inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
US20240200085A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
PL182089B1 (en) * 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
WO1996040966A1 (en) 1995-06-07 1996-12-19 Private Biologicals Corporation Compositions and methods of treating il-6 associated diseases

Also Published As

Publication number Publication date
WO2000010607A1 (en) 2000-03-02
JP4711507B2 (ja) 2011-06-29
CA2341239C (en) 2011-01-04
US8440196B1 (en) 2013-05-14
DE69934698T2 (de) 2007-10-04
AU5304999A (en) 2000-03-14
DK1108435T3 (da) 2007-02-05
EP1108435B1 (de) 2007-01-03
PT1108435E (pt) 2007-04-30
AU757261B2 (en) 2003-02-13
EP1108435A4 (de) 2002-05-08
ES2276525T3 (es) 2007-06-16
CA2341239A1 (en) 2000-03-02
DE69934698D1 (de) 2007-02-15
EP1108435A1 (de) 2001-06-20

Similar Documents

Publication Publication Date Title
DE69934698D1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
EP1074268A4 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes mit il-6 antagonisten als aktiven inhaltsstoffen
TR200002965T2 (tr) Enfeksiyonların terapötik ve profilaktik tedavisi için organofosforlu terkiplerin kullanımı
NO971546D0 (no) Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
ATE301994T1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda- antagonist
DE69829558D1 (de) Sulfonamide für die behandlung von störungen durch endothelin vermittelt
ES2170815T3 (es) Potenciador de agente antitumoral que comprende un antagonista de il-6.
DE69713485D1 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE69307617D1 (de) Verwendung von Kompetitiven NMDA-Rezeptorantagonisten zur Behandlung der Harninkontinenz
DE50011178D1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ATE346867T1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
ATE332145T1 (de) Arzneien zur begleitenden behandlung von glaukomen
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
DE60210101D1 (de) Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten
DE69731658D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
DK1169058T3 (da) Insulinlignende vækstfaktorbindingsprotein-4-protease
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
DE69426986D1 (de) Behandlung von laminitis
DE69935662D1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1108435

Country of ref document: EP